# US 2025/0152616 A1 · Compositions for and methods of treating, preventing, and/or mitigating pain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152616 A1
- Document ID: US20250152616A1
- Status: Published application
- Kind: A1
- Application number: 18/726,920
- Filed: 2023-01-05
- Published: 2025-05-15
- Earliest claimed: 2022-01-06
- Assignees: Duke University
- Applicants: Duke University
- Inventors: Shyni Varghese; Yu Ru Shih
- Web page: https://patentgrep.com/patent/US20250152616A1

## CPC

- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61P 25/36: Opioid-abuse
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are compositions for and methods of treating, preventing, and/or mitigating pain, including both acute and chronic pain, post-surgical pain, cancer pain, injury pain, and pain associated with bone fracture. Disclosed herein are compositions for and methods of providing non-opioid analgesia in a subject in need thereof.

## Claims

### Claim 1

A method of treating, preventing, and/or mitigating pain in a subject, the method comprising:
administering to a subject having pain a biomaterial comprising a therapeutically effective amount of adenosine, wherein the subject's pain is reduced.

### Claim 2

A method of treating a subject in need of non-opioid analgesia, the method comprising:
administering to a subject having pain a biomaterial comprising a therapeutically effective amount of adenosine; wherein the subject's pain is reduced.

### Claim 3 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the therapeutically effective amount of adenosine comprises from about 1 mg/kg to about 30 mg/kg of subject's body weight.

### Claim 4 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the biomaterial comprises a macroporous hydrogel.

### Claim 5 (depends on 4)

The method of claim 4, wherein the biomaterial comprises from about 0.1 mg to about 1.0 mg of adenosine per 1 mg of macroporous hydrogel.

### Claim 6 (depends on 4)

The method of claim 4, wherein the macroporous hydrogel comprises poly(ethylene glycol)-co-6 aminocaproic acid.

### Claim 7 (depends on 6)

The method of claim 6, wherein the macroporous hydrogel is functionalized with 3-(acrylamido)phenylboronic acid (3-APBA).

### Claim 8 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the subject has an opioid dependence, has recovered from an opioid dependence, or is an active recovery from an opioid dependence.

### Claim 9 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the pain comprises acute pain or chronic pain, post-surgical pain, cancer pain, injury pain, or any combination thereof.

### Claim 10 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the subject is a non-human mammal or a human.

### Claim 11 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the pain is associated with one or more bone fractures.

### Claim 12 (depends on 11)

The method of claim 11, wherein the one or more bone fractures are the result of a non-trauma, a disease, or a disorder.

### Claim 13 (depends on 11)

The method of claim 11, wherein the one or more bone fractures are the result of an injury, a surgery, or a physical trauma.

### Claim 14 (depends on 11)

The method of claim 11, wherein administering comprises implanting the biomaterial at or near the one or more bone fractures.

### Claim 15 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the subject's pain is not the result of one or more bone fractures.

### Claim 16 (depends on 15)

The method of claim 15, wherein administering comprises implanting the biomaterial at or near the source of the subject's pain.

### Claim 17 (depends on 1, 2)

The method of claim 1 or claim 2, further comprising improving the subject's ability to move and/or ambulate.

### Claim 18 (depends on 1, 2)

The method of claim 1 or claim 2, further comprising improving the subject's ability to bear weight.

### Claim 19 (depends on 1, 2)

The method of claim 1 or claim 2, further comprising reducing functional activity of one or more dorsal root ganglion neurons.

### Claim 20 (depends on 19)

The method of claim 19, wherein reducing the functional activity of one or more dorsal root ganglion neurons comprises increasing the level of ADORA1 activation and/or expression.

### Claim 21 (depends on 11)

The method of claim 11, further comprising promoting healing of the one or more bone fractures.

### Claim 22 (depends on 11)

The method of claim 11, further comprising enhancing the innate ability of bone repair tissue to repair the one or more bone fractures.

### Claim 23 (depends on 11)

The method of claim 11, further comprising reducing bone degeneration in the subject and/or promoting bone regeneration in the subject.

### Claim 24 (depends on 11)

The method of claim 11, further comprising promoting osteoblastogenesis in or around the area of the one or more bone fractures.

### Claim 25 (depends on 24)

The method of claim 24, further comprising increasing the level of ADORA2B activation and/or expression in mesenchymal stromal cells.

### Claim 26 (depends on 1, 2)

The method of claim 1 or claim 2, further comprising administering to the subject one or more additional therapeutic agents.

### Claim 27 (depends on 26)

The method of claim 26, wherein the additional therapeutic agents comprise one or more non-steroidal anti-inflammatory agents (NSAIDs).

### Claim 28 (depends on 26)

The method of claim 26, wherein the additional therapeutic agents comprise one or more opioids.

### Claim 29 (depends on 1, 2)

The method of claim 1 or claim 2, further comprising repeating one or more times the administering of the biomaterial.

### Claim 30 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the subject's ability to move and/or ambulate is improved, the subject's ability to bear weight is improved, the innate ability of bone repair tissue to repair the one or more bone fractures is enhanced, bone degeneration is decreased, bone regeneration is promoted, osteoblastogenesis in or around the area of the one or more bone fractures is increased, the level of ADORA2B activation and/or ADORA2A expression in mesenchymal stromal cells is increased, the level of ADORA1 activation and/or ADORA1 expression in sensory neurons is increased, or any combination thereof.

### Claim 31 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the method does not require administering to the subject one or more opioids.
